Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study

Qilu Pharmaceutical

Status and phase

Completed

Phase 3

Conditions

Acute Ischemic Stroke

Treatments

Drug: Monosialoganglioside

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT06742216

QLGM1-AIS-301

Details and patient eligibility

About

A multicenter, randomized, double-blind, parallel, placebo-controlled trial design is used to evaluate the efficacy and safety of GM1 injection in the treatment of patients with acute ischemic stroke.

It is estimated that 1706 patients will be enrolled and randomly assigned to the treatment group and the placebo control group in a 1:1 ratio. Normally, the duration of this study is approximately 90 days.

Treatment was continued for 12~14 days, and follow-up was conducted until the 90th day from the first dose.

The trial is divided into three phases: screening/baseline phase, treatment phase, and follow-up phase.

Screening/baseline period: After the subjects sign the informed consent form, they enter the screening/baseline period for screening examination.

Treatment period: Qualified subjects are randomly divided into groups in a 1:1 ratio and receive continuous treatment for 12~14 days (12~14 times) with GM1 injection and placebo respectively. During the treatment period, relevant examinations and evaluations required by the protocol will be carried out.

Follow-up period: Subjects who have completed treatment will enter the follow-up period until the 90th day of treatment.

Enrollment

1,232 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age: 18-80 years old；
Patients with anterior circulation cerebral infarction; first stroke onset or past stroke without obvious neurological deficit (mRS score≤1)；
Within 24 hours of onset；
7 ≤NIHSS score ≤ 20；
Signed informed consent.

Exclusion criteria

Patients with hereditary abnormal glucose and lipid metabolism (gangliosidosis, such as Tay-Sachs disease and retinal degeneration);
Hemorrhagic stroke;
Disturbance of consciousness (NIHSS1a≥1)，or cerebral arteritis, brain tumor, brain trauma, intracranial infectious diseases;
Planed endovascular treatment;
Uncontrolled hypertension: systolic pressure ≥200 mmHg or diastolic pressure ≥110 mmHg;
Bleeding tendency (except for thrombolysis) or severe bleeding within 3 months;
Patients with malignant tumor or serious diseases;
Along with epilepsy, arthritis and other disease, which have effect on neurological assessment;
History of autoimmune diseases, spinal trauma, various demyelinating diseases, including acute inflammatory demyelinating polyneuropathy (Guillain Barre syndrome);
Unable or unwilling to cooperate due to mental diseases;
Abnormal liver and renal function: ALT, AST > 2 times of the upper limit of normal value, or Cr > 1.5 times of the upper limit of normal value；
Hypersensitivity to monosialoganglioside and excipients of test drug;
History of drug abuse；
Pregnant or lactating women, pregnant plan or unwilling to use effective contraception during the trial period;
Participating in other clinical trials within 3 months;
Other conditions which are unsuitable for this trial assessed by researcher.